# A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

> **NCT00743769** · PHASE1 · WITHDRAWN · sponsor: **RegeneRx Biopharmaceuticals, Inc.**

## Conditions studied

- Myocardial Infarction
- Myocardial Ischemia

## Interventions

- **DRUG:** thymosin beta 4
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00743769
- **Lead sponsor:** RegeneRx Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-04
- **Primary completion:** 2017-01-01
- **Final completion:** 2017-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never initiated due to contract manufacturing issues
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743769, "A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00743769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*